Krystal Biotech, Inc.·4

Jun 5, 6:40 PM ET

Krishnan Suma 4

4 · Krystal Biotech, Inc. · Filed Jun 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Krystal Biotech (KRYS) 10% Owner Suma Krishnan Sells 25,000 Shares

What Happened
Suma Krishnan, reported as a 10% owner of Krystal Biotech (KRYS), sold a total of 25,000 shares in open-market transactions on June 4, 2026. The sales were executed in multiple trades at prices ranging roughly from $300.75 to $311.77. Major blocks included 12,729 shares at $307.81 ($3,918,070) and other lots (e.g., 3,803 shares at $308.89 for $1,174,708); total reported proceeds were approximately $7,702,826. These were dispositions (S = sale), not purchases.

Key Details

  • Date of transactions: June 4, 2026 (Form 4 filed June 5, 2026 — timely filing).
  • Shares sold: 25,000 shares; total proceeds ≈ $7,702,826.
  • Price details: individual lots reported at weighted-average prices from $300.75 up to $311.77; several footnotes (F3–F12) note the sales were executed in multiple trades within specified price ranges and the listed prices are weighted averages.
  • Plan: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted September 4, 2025 (plan effective December 4, 2025 through December 4, 2026 unless earlier terminated) (F2).
  • Post-transaction holdings: the Form 4 does not disclose the reporting person’s remaining beneficial ownership in this filing.
  • Related-party/trust notes: the filing disclaims beneficial ownership of shares directly owned by the reporting person’s spouse (reported separately) and references family/spousal trusts (F1, F13, F14).

Context

  • These were planned dispositions under a 10b5‑1 plan — common for insiders to sell on a pre-set schedule; such sales are generally treated as routine rather than a direct signal of changing sentiment.
  • As a 10% owner (not necessarily an executive transaction), the trades reflect an insider-level stakeholder selling shares; no options were exercised and no awards or gifts were reported in this filing.

Insider Transaction Report

Form 4
Period: 2026-06-04
Krishnan Suma
DirectorPresident, R&D10% Owner
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-06-04$300.75/sh320$96,2401,402,835 total
  • Sale

    Common Stock

    [F3]
    2026-06-04$302.25/sh593$179,2351,402,242 total
  • Sale

    Common Stock

    [F4]
    2026-06-04$303.17/sh247$74,8831,401,995 total
  • Sale

    Common Stock

    [F5]
    2026-06-04$304.89/sh400$121,9581,401,595 total
  • Sale

    Common Stock

    [F6]
    2026-06-04$305.87/sh480$146,8151,401,115 total
  • Sale

    Common Stock

    [F7]
    2026-06-04$307.09/sh1,348$413,9641,399,767 total
  • Sale

    Common Stock

    [F8]
    2026-06-04$307.81/sh12,729$3,918,0701,387,038 total
  • Sale

    Common Stock

    [F9]
    2026-06-04$308.89/sh3,803$1,174,7081,383,235 total
  • Sale

    Common Stock

    [F10]
    2026-06-04$309.95/sh2,801$868,1561,380,434 total
  • Sale

    Common Stock

    [F11]
    2026-06-04$310.94/sh2,039$634,0011,378,395 total
  • Sale

    Common Stock

    [F12]
    2026-06-04$311.65/sh240$74,7961,378,155 total
Holdings
  • Common Stock

    [F13]
    (indirect: By Trust)
    90,000
  • Common Stock

    [F14]
    (indirect: By Trust)
    50,000
Footnotes (14)
  • [F1]The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
  • [F10]The transaction was executed in multiple trades ranging from $309.43 to $310.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F11]The transaction was executed in multiple trades ranging from $310.44 to $311.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F12]The transaction was executed in multiple trades ranging from $311.50 to $311.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F13]Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
  • [F14]Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
  • [F2]The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025, and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
  • [F3]The transaction was executed in multiple trades ranging from $302.05 to $303.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F4]The transaction was executed in multiple trades ranging from $303.05 to $303.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F5]The transaction was executed in multiple trades ranging from $304.07 to $304.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F6]The transaction was executed in multiple trades ranging from $305.19 to $306.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F7]The transaction was executed in multiple trades ranging from $306.38 to $307.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F8]The transaction was executed in multiple trades ranging from $307.38 to $308.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F9]The transaction was executed in multiple trades ranging from $308.38 to $309.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Signature
/s/ Suma M. Krishnan|2026-06-05

Documents

1 file
  • 4
    wk-form4_1780699235.xmlPrimary

    FORM 4